Literature DB >> 24919418

Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.

K Watcharanurak1, L Zang1, M Nishikawa1, K Yoshinaga2, Y Yamamoto2, Y Takahashi1, M Ando1, K Saito2, Y Watanabe3, Y Takakura1.   

Abstract

Interferon γ (IFN-γ), an anticancer agent, is a strong inducer of indoleamine 2,3-dioxygenase 1 (IDO1), which is a tryptophan-metabolizing enzyme involved in the induction of tumor immune tolerance. In this study, we investigated the IDO1 expression in organs after IFN-γ gene transfer to mice. IFN-γ gene transfer greatly increased the mRNA expression of IDO1 in many tissues with the highest in the liver. This upregulation was associated with reduced L-tryptophan levels and increased L-kynurenine levels in serum, indicating that IFN-γ gene transfer increased the IDO activity. Then, Lewis lung carcinoma (LLC) tumor-bearing wild-type and IDO1-knockout (IDO1 KO) mice were used to investigate the effects of IDO1 on the antitumor activity of IFN-γ. IFN-γ gene transfer significantly retarded the tumor growth in both strains without any significant difference in tumor size between the two groups. By contrast, the IDO1 activity was increased only in the wild-type mice by IFN-γ gene transfer, suggesting that cells other than LLC cells, such as tumor stromal cells, are the major contributors of IDO1 expression in LLC tumor. Taken together, these results imply that IFN-γ gene transfer mediated IDO1 upregulation in cells other than LLC cells has hardly any effect on the antitumor activity of IFN-γ.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24919418     DOI: 10.1038/gt.2014.54

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Joanna S Kerley-Hamilton; Haley F Hazlett; Krishnamurthy V Nemani; Heidi W Trask; Rachel J West; Leslie E Lupien; Alan J Collins; Carol S Ringelberg; Barjor Gimi; William B Kinlaw; Craig R Tomlinson
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-25       Impact factor: 4.219

2.  Dendritic Cells Treated with Exogenous Indoleamine 2,3-Dioxygenase Maintain an Immature Phenotype and Suppress Antigen-specific T cell Proliferation.

Authors:  Evelyn Bracho-Sanchez; Azadeh Hassanzadeh; Maigan A Brusko; Mark A Wallet; Benjamin G Keselowsky
Journal:  J Immunol Regen Med       Date:  2019-02-10

3.  Quantification of IDO1 enzyme activity in normal and malignant tissues.

Authors:  Lijie Zhai; Erik Ladomersky; April Bell; Corey Dussold; Krislyn Cardoza; Jun Qian; Kristen L Lauing; Derek A Wainwright
Journal:  Methods Enzymol       Date:  2019-07-24       Impact factor: 1.600

Review 4.  Presentation of hepatocellular antigens.

Authors:  Arash Grakoui; Ian Nicholas Crispe
Journal:  Cell Mol Immunol       Date:  2016-02-29       Impact factor: 11.530

Review 5.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106

6.  Contribution of Epigenetic Modifications to the Decline in Transgene Expression from Plasmid DNA in Mouse Liver.

Authors:  Lei Zang; Makiya Nishikawa; Mitsuru Ando; Yuki Takahashi; Yoshinobu Takakura
Journal:  Pharmaceutics       Date:  2015-08-07       Impact factor: 6.321

7.  Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1.

Authors:  Bruno Lopes-Bastos; Liang Jin; Fiona Ruge; Sioned Owen; Andrew Sanders; Christopher Cogle; John Chester; Wen G Jiang; Jun Cai
Journal:  Oncotarget       Date:  2017-06-28

8.  Overexpression of indoleamine 2, 3-dioxygenase contributes to the repair of human airway epithelial cells inhibited by dexamethasone via affecting the MAPK/ERK signaling pathway.

Authors:  Shanshan Jia; Pin Guo; Xiangjin Ge; Huanhuan Wu; Junhua Lu; Xiaofang Fan
Journal:  Exp Ther Med       Date:  2018-05-14       Impact factor: 2.447

9.  Non-cytotoxic doses of shikonin inhibit lipopolysaccharide-induced TNF-α expression via activation of the AMP-activated protein kinase signaling pathway.

Authors:  Fang Zhang; Tao Pan; Xiaohui Wu; Xingchun Gao; Zhikui Li; Xinling Ren
Journal:  Exp Ther Med       Date:  2020-09-03       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.